MA56502A - Promédicaments à base de quinazoline pour le traitement d'infections virales et d'autres maladies - Google Patents
Promédicaments à base de quinazoline pour le traitement d'infections virales et d'autres maladiesInfo
- Publication number
- MA56502A MA56502A MA056502A MA56502A MA56502A MA 56502 A MA56502 A MA 56502A MA 056502 A MA056502 A MA 056502A MA 56502 A MA56502 A MA 56502A MA 56502 A MA56502 A MA 56502A
- Authority
- MA
- Morocco
- Prior art keywords
- quinazoline
- prodrugs
- diseases
- treatment
- viral infections
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19180951 | 2019-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56502A true MA56502A (fr) | 2022-04-27 |
Family
ID=66998187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056502A MA56502A (fr) | 2019-06-18 | 2020-06-18 | Promédicaments à base de quinazoline pour le traitement d'infections virales et d'autres maladies |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220324817A1 (fr) |
| EP (1) | EP3986871B1 (fr) |
| JP (1) | JP2022538398A (fr) |
| KR (1) | KR20220024441A (fr) |
| CN (1) | CN114008029A (fr) |
| AU (1) | AU2020294920A1 (fr) |
| BR (1) | BR112021024648A2 (fr) |
| CA (1) | CA3138592A1 (fr) |
| ES (1) | ES2951169T3 (fr) |
| MA (1) | MA56502A (fr) |
| MX (1) | MX2021015494A (fr) |
| WO (1) | WO2020254473A1 (fr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997020821A1 (fr) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Derives heteroaryles |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| CA2732437C (fr) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Formulations d'agoniste des recepteurs de type toll et leur utilisation |
| US20120082658A1 (en) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Methods for the Treatment of Allergic Diseases |
| PL2709989T3 (pl) * | 2011-05-18 | 2018-06-29 | Janssen Sciences Ireland Uc | Pochodne chinazoliny do leczenia infekcji wirusowych i dalszych chorób |
| SG11201606876RA (en) * | 2015-03-04 | 2016-10-28 | Gilead Sciences Inc | Toll like receptor modulator compounds |
| AU2017238758B2 (en) * | 2016-03-21 | 2021-01-21 | Council Of Scientific & Industrial Research | Blocking toll-like receptor 9 signaling with small molecule antagonist |
-
2020
- 2020-06-18 ES ES20733429T patent/ES2951169T3/es active Active
- 2020-06-18 CN CN202080044824.2A patent/CN114008029A/zh not_active Withdrawn
- 2020-06-18 BR BR112021024648A patent/BR112021024648A2/pt not_active Application Discontinuation
- 2020-06-18 CA CA3138592A patent/CA3138592A1/fr active Pending
- 2020-06-18 WO PCT/EP2020/066896 patent/WO2020254473A1/fr not_active Ceased
- 2020-06-18 MA MA056502A patent/MA56502A/fr unknown
- 2020-06-18 US US17/596,022 patent/US20220324817A1/en not_active Abandoned
- 2020-06-18 KR KR1020227000552A patent/KR20220024441A/ko not_active Withdrawn
- 2020-06-18 EP EP20733429.3A patent/EP3986871B1/fr active Active
- 2020-06-18 JP JP2021575449A patent/JP2022538398A/ja not_active Withdrawn
- 2020-06-18 AU AU2020294920A patent/AU2020294920A1/en not_active Abandoned
- 2020-06-18 MX MX2021015494A patent/MX2021015494A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138592A1 (fr) | 2020-12-24 |
| JP2022538398A (ja) | 2022-09-02 |
| EP3986871A1 (fr) | 2022-04-27 |
| EP3986871C0 (fr) | 2023-06-07 |
| ES2951169T3 (es) | 2023-10-18 |
| MX2021015494A (es) | 2022-04-18 |
| US20220324817A1 (en) | 2022-10-13 |
| KR20220024441A (ko) | 2022-03-03 |
| WO2020254473A1 (fr) | 2020-12-24 |
| AU2020294920A1 (en) | 2022-02-17 |
| EP3986871B1 (fr) | 2023-06-07 |
| CN114008029A (zh) | 2022-02-01 |
| BR112021024648A2 (pt) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3765611A4 (fr) | Oligonucléotides ciblant la pcsk9 pour le traitement de l'hypercholestérolémie et d'états apparentés | |
| MA52219A (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| EP3908270A4 (fr) | Combinaison de dextrométhorphane et de bupropion pour le traitement de la dépression | |
| EP4045036A4 (fr) | Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1 | |
| EP3937932A4 (fr) | Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses | |
| EP3976059A4 (fr) | Traitement de maladies associées à l'angiopoïétine 7 (angptl7) | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3463315A4 (fr) | Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale | |
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| EP3490987A4 (fr) | Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv. | |
| EP3986426A4 (fr) | Ciblage de l'intégrine alpha3bêta1 pour le traitement du cancer et d'autres maladies | |
| EP3463341A4 (fr) | Immunomodulateurs à base d'aminocylindazole pour le traitement de maladies auto-immunes | |
| EP3960858A4 (fr) | Petit médicament à base d'arn pour la prévention et le traitement de maladies liées à une l'inflammation et leur combinaison | |
| EP4058037A4 (fr) | Thérapie à base de fibroblastes pour le traitement et la prévention d'un accident vasculaire cérébral | |
| EP3445352A4 (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| EP3743091A4 (fr) | Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc | |
| EP3781584A4 (fr) | Promédicaments de 4'-thio-nucléotide et de nucléoside pour le traitement du cancer | |
| EP3773629A4 (fr) | Thérapies à base de car-treg pour le traitement de maladies neurodégénératives | |
| EP3735260A4 (fr) | Peptides thérapeutiques et méthodes de traitement de maladies liées à l'auto-immunité | |
| EP3649256A4 (fr) | Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1 | |
| MA55720A (fr) | Polythérapie pour le traitement d'une infection par le virus de l'hépatite b | |
| EP3471738A4 (fr) | Dérivés de nucléosides cycliques à substitution phosphate et leurs procédés d'utilisation pour le traitement de maladies virales | |
| EP3861131A4 (fr) | Thérapie génique pour le traitement de l'acidémie propionique |